| Gene name: | ILK |
| Aging type: | Prevent |
| Aging characteristic: |
| Tissue type: | -- |
| Cell name: | Rb116,Y79 |
| Gene ID: | 3611 |
| Category: | protein coding |
| Phenotype: | Human retinoblastoma |
| Experimental category: | L |
| PMID: | 26176204 |
| Experiment: | SA-β-gal activity assay//Knockdown//Flow cytometry |
| Description: | ILK knockdown significantly increased SA-β-gal activity in Rb116 cells as compared to control. As has been shown previously for Rb-negative retinoblastoma cell lines, a 5-day exposure to QLT-0267 significantly increased the fraction of Y79 cells in G2+M-phase. The percentage of cells in G2+M-phase was 39.6 ± 5% as compared to 24.6 ± 2.1% in vehicle control. |
| Target gene: | RB |
| Official symbol(s): | RB |
| R-AG-Target gene: | -- |
| Subcategory: | Unclear |
| Target gene experiment: | SA-β-gal activity assay |
| Target gene description: | ILK siRNA treatment increased SA-β-gal activity in Rb positive cells but not Rb deficient cells. |
| Regulatory pathway: | -- |
| R-AG-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation:
Loading,please wait...